Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31433037 | 1.00 | NR1H2 (0.57) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL22413118 | 1.00 | NR1H2 (0.57) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL22413119 | 1.00 | NR1H2 (0.57) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29105865 | 1.00 | NR1H2 (0.57) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL9965499 | 1.00 | NR1H2 (0.57) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL216412 | 0.92 | NR1H2 (0.56) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL2917798 | 0.89 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29105861 | 0.89 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL2917795 | 0.89 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL29105803 | 0.89 | NR1H2 (0.51) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2025-01-23 | — | — | US | disclosed |
| WO-2025006753-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2024-10-01 | — | — | US | disclosed |
| CN-117062811-A | 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and medical use thereof | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-01-19 | — | — | US | disclosed |
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | 2022-05-12 | — | — | US | disclosed |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| WO-2020186196-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2020-09-17 | — | — | WO | disclosed |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-04-14 | — | — | US | disclosed |
| EP-3099695-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2017172763-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| US-20170015668-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-19 | — | — | US | disclosed |
| WO-2015113452-A1 | COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885 |
| US-10618901-B2 | LRRK2 inhibitors for the treatment of Parkinson's disease | LRRK2, PARK7, PINK1 | NR1H2 4038/4885CHRM2 3081/4885CHRM1 3327/4885 |
| US-20230019617-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885 |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | POLRMT, CNBP, DHPS | NR1H2 1515/4885CHRM2 4501/4885CHRM1 3901/4885 |
| US-12103919-B2 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | HBZ, HBG1, HBG2 | NR1H2 734/4885CHRM2 4722/4885CHRM1 4635/4885 |
| US-20220144841-A1 | TRISUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINE COMPOUNDS AS CDK7 INHIBITORS | CDK7, CDK8, CDK3 | NR1H2 3313/4885CHRM2 4475/4885CHRM1 3806/4885 |
| US-10906033-B2 | Synthesis and application of chiral substituted polyvinylpyrrolidinones | POLRMT, CNBP, DHPS | NR1H2 1515/4885CHRM2 4501/4885CHRM1 3901/4885 |
| US-20170015668-A1 | COMPOUNDS | LRRK2, PARK7, PINK1 | NR1H2 3549/4885CHRM2 2760/4885CHRM1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.